JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, D. H.
Right arrow Articles by Gaydos, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, D. H.
Right arrow Articles by Gaydos, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2004, p. 4749-4758, Vol. 42, No. 10
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.10.4749-4758.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Use of Multiple Nucleic Acid Amplification Tests To Define the Infected-Patient "Gold Standard" in Clinical Trials of New Diagnostic Tests for Chlamydia trachomatis Infections

David H. Martin,1* Malanda Nsuami,1 Julius Schachter,2 Edward W. Hook III,3 Dennis Ferrero,4 Thomas C. Quinn,5,6 and Charlotte Gaydos5

Health Sciences Center, Louisiana State University, New Orleans, Louisiana,1 University of San Francisco, San Francisco,2 San Joaquin County Public Health Department, San Joaquin, California,4 University of Alabama at Birmingham, Birmingham, Alabama,3 Johns Hopkins University, Baltimore,5 National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland6

Received 11 October 2003/ Returned for modification 7 January 2004/ Accepted 5 July 2004

Nucleic acid amplification tests (NAATs) can be used to define the infected-patient "gold standard" for the purpose of designing studies of the performance of Chlamydia trachomatis diagnostic tests. It is unclear how many test results run by different NAATs and what combinations of specimens comprise the best infected-patient gold standard. We approached this question with data from a large study of the performance of a new NAAT. Data were available from three endocervical swabs and a urine specimen collected from each of 1,412 women and tested by three different NAATs. Results from all three assays were used equally in a rotating fashion to define the infected-patient gold standard. Multiple different infected-patient gold standards for estimating swab and urine specimen sensitivity and specificity for one NAAT method were created by varying the number and combinations of swab and urine comparator results with two different NAATs, The effect of changing the infected-patient gold standard definition was determined by constructing receiver-operator-like curves with calculated sensitivities and specificities for each test. The one-positive-of-two-results or two-positive-of-two-results (same or two different assays) infected-patient gold standard definitions produced low sensitivity and low specificity estimates, respectively. If four comparator NAAT results were used, the any-three-positive-of-four-results definition or the at-least-one-specimen-positive-by-each-of-two-comparator-assays definition appeared to provide better combinations of sensitivity and specificity estimates. The any-two-positive-out-of-three-results definition resulted in estimates that were as good as produced with the former two definitions. This analytic approach provides a means of clearly visualizing the effects of changing NAAT-based infected-patient gold standards and should be helpful in designing future studies of new C. trachomatis diagnostic tests.

* Corresponding author. Mailing address: LSU Health Sciences Center, Department of Medicine, Section of Infectious Diseases, 1542 Tulane Ave., New Orleans LA 70112. Phone: (504) 568-5031. Fax: (504) 568-6752. E-mail: dhmartin{at}lsuhsc.edu.

Journal of Clinical Microbiology, October 2004, p. 4749-4758, Vol. 42, No. 10
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.10.4749-4758.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.